Invex Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-0.84	-0.48	-1.64	-7.75	-3.95	-2.28
Stock-Based Compensation	0.02	0.02	0.14	0.48	0.35	0.56
Other Operating Activities	-0.16	0.02	-0.04	0.02	0	0
Change in Accounts Receivable	-0	-0	0.24	-0.19	-0.12	0.1
Change in Accounts Payable	-0.21	-0.21	-1.14	0.57	0.35	-0.05
Operating Cash Flow	-1.19	-0.65	-2.44	-6.87	-3.38	-1.68
Issuance of Common Stock	-	-	-	-	-	8.65
Repurchase of Common Stock	-	-	-14	-	-	-
Other Financing Activities	-	-	-	-	-	-0.55
Financing Cash Flow	-	-	-14	-	-	8.09
Foreign Exchange Rate Adjustments	-0.02	0	-	-	-	-
Net Cash Flow	-1.21	-0.65	-16.45	-6.87	-3.38	6.42
Cash Income Tax Paid	-	-0.23	-1.21	-0.46	-	-
Levered Free Cash Flow	-1.05	-0.64	-2.1	-4.48	-1.95	-2.23
Unlevered Free Cash Flow	-1.05	-0.64	-2.1	-4.48	-1.95	-2.23
Change in Working Capital	-0.21	-0.21	-0.9	0.38	0.22	0.04

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.